← Novocure overview

Novocure vs Integer: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Novocure Ltd (NVCR)

Q3 2026
▲2▼2

TRIDENT flop then pancreatic CE Mark and raised guidance lift Novocure

  • TRIDENT trial fails primary endpoint Novocure's Phase 3 TRIDENT trial missed its main goal: starting Tumor Treating Fields earlier did not clearly extend overall survival in newly diagnosed glioblastoma. The stock fell about 20% as hopes for a broader label in this cancer faded.

    This is the period's biggest negative event and explains the initial sharp drop.

  • Securities fraud investigation after TRIDENT Law firm Pomerantz is investigating Novocure for possible securities fraud tied to the TRIDENT miss. Such probes can bring legal costs, distract management, and keep some investors cautious, adding pressure on the shares.

    It is a new legal overhang directly linked to the trial failure.

  • Optune Pax wins CE Mark for pancreatic cancer Novocure's Optune Pax received European CE Mark approval for locally advanced pancreatic cancer, backed by the PANOVA-3 trial showing longer survival and delayed pain. Launch starts in Germany, opening a new market and revenue stream.

    This is a fresh regulatory win that expands the addressable market beyond brain cancer.

  • Q2 revenue beat and raised 2026 guidance Second-quarter revenue rose 16% to $183.6 million, and Novocure raised full-year 2026 revenue guidance to $710–$725 million while projecting positive adjusted EBITDA. The stock hit a 52-week high as investors grew more confident in the core business.

    This is the main positive catalyst that reversed the earlier decline and drove the new high.

July 2026
▲2▼2

TRIDENT flop then pancreatic CE Mark and raised guidance lift Novocure

  • TRIDENT trial fails primary endpoint Novocure's Phase 3 TRIDENT trial missed its main goal: starting Tumor Treating Fields earlier did not clearly extend overall survival in newly diagnosed glioblastoma. The stock fell about 20% as hopes for a broader label in this cancer faded.

    This is the period's biggest negative event and explains the initial sharp drop.

  • Securities fraud investigation after TRIDENT Law firm Pomerantz is investigating Novocure for possible securities fraud tied to the TRIDENT miss. Such probes can bring legal costs, distract management, and keep some investors cautious, adding pressure on the shares.

    It is a new legal overhang directly linked to the trial failure.

  • Optune Pax wins CE Mark for pancreatic cancer Novocure's Optune Pax received European CE Mark approval for locally advanced pancreatic cancer, backed by the PANOVA-3 trial showing longer survival and delayed pain. Launch starts in Germany, opening a new market and revenue stream.

    This is a fresh regulatory win that expands the addressable market beyond brain cancer.

  • Q2 revenue beat and raised 2026 guidance Second-quarter revenue rose 16% to $183.6 million, and Novocure raised full-year 2026 revenue guidance to $710–$725 million while projecting positive adjusted EBITDA. The stock hit a 52-week high as investors grew more confident in the core business.

    This is the main positive catalyst that reversed the earlier decline and drove the new high.

Latest
▲2▼2

TRIDENT flop then pancreatic CE Mark and raised guidance lift Novocure

  • TRIDENT trial fails primary endpoint Novocure's Phase 3 TRIDENT trial missed its main goal: starting Tumor Treating Fields earlier did not clearly extend overall survival in newly diagnosed glioblastoma. The stock fell about 20% as hopes for a broader label in this cancer faded.

    This is the period's biggest negative event and explains the initial sharp drop.

  • Securities fraud investigation after TRIDENT Law firm Pomerantz is investigating Novocure for possible securities fraud tied to the TRIDENT miss. Such probes can bring legal costs, distract management, and keep some investors cautious, adding pressure on the shares.

    It is a new legal overhang directly linked to the trial failure.

  • Optune Pax wins CE Mark for pancreatic cancer Novocure's Optune Pax received European CE Mark approval for locally advanced pancreatic cancer, backed by the PANOVA-3 trial showing longer survival and delayed pain. Launch starts in Germany, opening a new market and revenue stream.

    This is a fresh regulatory win that expands the addressable market beyond brain cancer.

  • Q2 revenue beat and raised 2026 guidance Second-quarter revenue rose 16% to $183.6 million, and Novocure raised full-year 2026 revenue guidance to $710–$725 million while projecting positive adjusted EBITDA. The stock hit a 52-week high as investors grew more confident in the core business.

    This is the main positive catalyst that reversed the earlier decline and drove the new high.

Integer Holdings Corp (ITGR)

Q3 2026
▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

  • KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.

    This is the single new event that now sets ITGR's price, so it is the core answer.

  • No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.

    Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.

  • Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.

    Gives the honest counterweight: upside is limited and tied to completion, not to the business.

  • Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.

    It is the only negative force this period, but the buyout has largely overtaken it.

July 2026
▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

  • KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.

    This is the single new event that now sets ITGR's price, so it is the core answer.

  • No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.

    Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.

  • Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.

    Gives the honest counterweight: upside is limited and tied to completion, not to the business.

  • Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.

    It is the only negative force this period, but the buyout has largely overtaken it.

Latest
▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

  • KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.

    This is the single new event that now sets ITGR's price, so it is the core answer.

  • No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.

    Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.

  • Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.

    Gives the honest counterweight: upside is limited and tied to completion, not to the business.

  • Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.

    It is the only negative force this period, but the buyout has largely overtaken it.

© 2026 MarketIVWhy